Drug Trial Radar · NCT02680041
18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
Last checked: Nov 20, 2026Latest source record: Jan 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Jun 1, 2016
Primary completion
Nov 1, 2017
Study completion Nov 1, 2017
Sponsor
- Lead sponsor
- Blue Earth DiagnosticsIndustry
- Sponsor type
- Industry
- Collaborators
- American College of Radiology; IND 2 Results LLC; Syne Qua Non Limited
- First posted
- Feb 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging. Consenting participants will be imaged with 18F-fluciclovine PET/CT. Site clinicians will manage study subjects per standard practices and will document any change in treatment based on review of 18F-fluciclovine PET/CT findings. All participants will be followed for up to 6 months, with clinical data collected for this study. An interdisciplinary panel will provide expert guidance to local readers on request. The final reporting of the PET/CT scan will be a single report by the local reader following any such discussion.
Conditions
- Prostate Cancer
Interventions
18F-fluciclovine PET CTDrug
Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease.Time frame: 2-22 days post PET CT
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
Cedars-Sinai Medical Center
Los Angeles, California
Tower Urology
Los Angeles, California
Genesis Research, LLC
San Diego, California
University of Florida
Jacksonville, Florida
Loyola University Medical Center
Maywood, Illinois
Roudebush VA Medical Center
Indianapolis, Indiana
University of Louisville
Louisville, Kentucky
Washington University School of Medicine
St Louis, Missouri
Coastal Urology Associates
Brick, New Jersey
Manhattan Medical Research
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Urologic Consultants of SE Pennsylvania
Bala-Cynwyd, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.